{"id":57003,"date":"2026-02-12T22:07:16","date_gmt":"2026-02-12T14:07:16","guid":{"rendered":"https:\/\/flcube.com\/?p=57003"},"modified":"2026-02-12T22:07:19","modified_gmt":"2026-02-12T14:07:19","slug":"henlius-biotech-initiates-phase-ib-ii-study-for-hlx43-adc-combinations-in-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57003","title":{"rendered":"Henlius Biotech Initiates Phase Ib\/II Study for HLX43 ADC Combinations in Colorectal Cancer"},"content":{"rendered":"\n

Shanghai Henlius Biotech, Inc.<\/strong> (HKG:\u202f2696<\/a><\/strong>) announced first patient dosing<\/strong> in a Phase Ib\/II clinical study<\/strong> evaluating HLX43<\/strong>, a PD-L1-targeting antibody-drug conjugate (ADC)<\/strong>, in combination with HLX07 (anti-EGFR mAb)<\/strong> or HanSiZhuang (serplulimab, PD-1 mAb)<\/strong> for advanced or metastatic colorectal cancer (CRC)<\/strong>. The trial marks Henlius’s entry into ADC-based immuno-oncology combinations<\/strong>, leveraging its self-developed antibody platforms<\/strong> and licensed toxin-linker technology<\/strong>.<\/p>\n\n\n\n

Clinical Trial Design<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Shanghai Henlius Biotech, Inc. (HKG:\u202f2696)<\/td><\/tr>
Assets<\/strong><\/td>HLX43 (PD-L1 ADC) + HLX07 (anti-EGFR mAb) OR HanSiZhuang (PD-1 mAb)<\/td><\/tr>
Indication<\/strong><\/td>Advanced\/metastatic colorectal cancer (mCRC)<\/td><\/tr>
Study Phase<\/strong><\/td>Phase Ib\/II<\/td><\/tr>
Study Structure<\/strong><\/td>Part 1<\/strong>: Safety run-in + dose expansion; Part 2<\/strong>: Randomized efficacy evaluation<\/td><\/tr>
Part 2 Design<\/strong><\/td>HLX43 (2.0 or 2.5 mg\/kg) + HanSiZhuang (300 mg Q3W) vs. comparator<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Mechanism<\/h2>\n\n\n\n
Asset<\/th>Class<\/th>Mechanism<\/th>Origin<\/th><\/tr><\/thead>
HLX43<\/strong><\/td>PD-L1-targeting ADC<\/strong><\/td>PD-L1 antibody + DNA topoisomerase I inhibitor toxin<\/td>Licensed-in ADC technology<\/strong> + self-developed PD-L1 antibody<\/strong><\/td><\/tr>
HLX07<\/strong><\/td>Anti-EGFR monoclonal antibody<\/td>EGFR pathway blockade<\/td>In-house developed<\/strong><\/td><\/tr>
HanSiZhuang (serplulimab)<\/strong><\/td>PD-1 monoclonal antibody<\/td>Immune checkpoint inhibition<\/td>Self-developed<\/strong>; approved in China<\/strong> for 4 indications (sqNSCLC, ES-SCLC, ESCC, nsqNSCLC)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Combination Logic<\/h2>\n\n\n\n
Combination<\/th>Rationale<\/th>Strategic Value<\/th><\/tr><\/thead>
HLX43 + HLX07<\/strong><\/td>PD-L1 ADC + EGFR blockade<\/strong><\/td>Dual targeting of immune evasion and growth signaling; potential for RAS wild-type CRC<\/strong> population<\/td><\/tr>
HLX43 + HanSiZhuang<\/strong><\/td>PD-L1 ADC + PD-1 mAb<\/strong><\/td>Dual PD-L1\/PD-1 axis inhibition<\/strong> with cytotoxic payload; addresses primary and acquired resistance<\/strong> to checkpoint monotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Study Objectives & Biomarker Strategy<\/h2>\n\n\n\n
Endpoint Category<\/th>Specific Assessments<\/th>Innovation Focus<\/th><\/tr><\/thead>
Safety\/Tolerability<\/strong><\/td>Dose-limiting toxicities; MTD determination<\/td>ADC + immunotherapy combination safety profile<\/td><\/tr>
Efficacy<\/strong><\/td>ORR, DOR, PFS, OS (Part 2 randomized)<\/td>PD-L1 ADC mechanism validation<\/strong> in MSS CRC (typically immunotherapy-resistant)<\/td><\/tr>
Pharmacokinetics<\/strong><\/td>HLX43 exposure; immunogenicity<\/td>ADC PK optimization<\/strong> for combination setting<\/td><\/tr>
Biomarkers<\/strong><\/td>Predictive\/resistance markers<\/td>Patient selection strategy<\/strong> for Phase III design<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Positioning<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
CRC Immunotherapy Challenge<\/strong><\/td>95% of mCRC is MSS (microsatellite stable)<\/strong> \u2013 resistant to PD-1 monotherapy<\/strong>; ADC + IO combinations<\/strong> represent novel approach to overcome resistance<\/strong><\/td><\/tr>
Henlius Portfolio Synergy<\/strong><\/td>HanSiZhuang commercial infrastructure<\/strong> (4 approved indications) enables rapid CRC trial enrollment<\/strong> and combination therapy expertise<\/strong><\/td><\/tr>
ADC Competitive Landscape<\/strong><\/td>T-DXd (Enhertu)<\/strong>, sacituzumab govitecan (Trodelvy)<\/strong> lead in solid tumors; HLX43 PD-L1 targeting<\/strong> offers differentiation<\/strong> vs. HER2\/TROP2 ADCs<\/td><\/tr>
China CRC Market<\/strong><\/td>>380,000 new cases annually<\/strong>; limited targeted therapy options<\/strong> beyond anti-EGFR (RAS wild-type); significant unmet need<\/strong> in RAS-mutant population<\/td><\/tr>
Global Potential<\/strong><\/td>MSS CRC<\/strong> represents largest immunotherapy-resistant population<\/strong> globally; China-first data<\/strong> supports US\/EU partnership discussions<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding HLX43 clinical development in colorectal cancer, combination therapy efficacy in MSS tumors, and Henlius Biotech’s ADC platform validation. Actual results may differ due to Phase Ib\/II safety outcomes, competitive dynamics with established ADCs, and biomarker discovery success.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced first patient dosing in a Phase Ib\/II clinical study…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,62,29,270,862,18],"class_list":["post-57003","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-combination-therapy","tag-henlius-biotech","tag-hkg-2696","tag-pd-1-l1"],"yoast_head":"\nHenlius Biotech Initiates Phase Ib\/II Study for HLX43 ADC Combinations in Colorectal Cancer - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced first patient dosing in a Phase Ib\/II clinical study evaluating HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), in combination with HLX07 (anti-EGFR mAb) or HanSiZhuang (serplulimab, PD-1 mAb) for advanced or metastatic colorectal cancer (CRC). The trial marks Henlius's entry into ADC-based immuno-oncology combinations, leveraging its self-developed antibody platforms and licensed toxin-linker technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57003\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius Biotech Initiates Phase Ib\/II Study for HLX43 ADC Combinations in Colorectal Cancer\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced first patient dosing in a Phase Ib\/II clinical study evaluating HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), in combination with HLX07 (anti-EGFR mAb) or HanSiZhuang (serplulimab, PD-1 mAb) for advanced or metastatic colorectal cancer (CRC). The trial marks Henlius's entry into ADC-based immuno-oncology combinations, leveraging its self-developed antibody platforms and licensed toxin-linker technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57003\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-12T14:07:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-12T14:07:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57003#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57003\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius Biotech Initiates Phase Ib\\\/II Study for HLX43 ADC Combinations in Colorectal Cancer\",\"datePublished\":\"2026-02-12T14:07:16+00:00\",\"dateModified\":\"2026-02-12T14:07:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57003\"},\"wordCount\":451,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"Combination therapy\",\"Henlius Biotech\",\"HKG: 2696\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57003#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57003\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57003\",\"name\":\"Henlius Biotech Initiates Phase Ib\\\/II Study for HLX43 ADC Combinations in Colorectal Cancer - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-12T14:07:16+00:00\",\"dateModified\":\"2026-02-12T14:07:19+00:00\",\"description\":\"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced first patient dosing in a Phase Ib\\\/II clinical study evaluating HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), in combination with HLX07 (anti-EGFR mAb) or HanSiZhuang (serplulimab, PD-1 mAb) for advanced or metastatic colorectal cancer (CRC). The trial marks Henlius's entry into ADC-based immuno-oncology combinations, leveraging its self-developed antibody platforms and licensed toxin-linker technology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57003#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57003\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57003#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius Biotech Initiates Phase Ib\\\/II Study for HLX43 ADC Combinations in Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius Biotech Initiates Phase Ib\/II Study for HLX43 ADC Combinations in Colorectal Cancer - Insight, China's Pharmaceutical Industry","description":"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced first patient dosing in a Phase Ib\/II clinical study evaluating HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), in combination with HLX07 (anti-EGFR mAb) or HanSiZhuang (serplulimab, PD-1 mAb) for advanced or metastatic colorectal cancer (CRC). The trial marks Henlius's entry into ADC-based immuno-oncology combinations, leveraging its self-developed antibody platforms and licensed toxin-linker technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57003","og_locale":"en_US","og_type":"article","og_title":"Henlius Biotech Initiates Phase Ib\/II Study for HLX43 ADC Combinations in Colorectal Cancer","og_description":"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced first patient dosing in a Phase Ib\/II clinical study evaluating HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), in combination with HLX07 (anti-EGFR mAb) or HanSiZhuang (serplulimab, PD-1 mAb) for advanced or metastatic colorectal cancer (CRC). The trial marks Henlius's entry into ADC-based immuno-oncology combinations, leveraging its self-developed antibody platforms and licensed toxin-linker technology.","og_url":"https:\/\/flcube.com\/?p=57003","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-12T14:07:16+00:00","article_modified_time":"2026-02-12T14:07:19+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57003#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57003"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius Biotech Initiates Phase Ib\/II Study for HLX43 ADC Combinations in Colorectal Cancer","datePublished":"2026-02-12T14:07:16+00:00","dateModified":"2026-02-12T14:07:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57003"},"wordCount":451,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","Combination therapy","Henlius Biotech","HKG: 2696","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57003#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57003","url":"https:\/\/flcube.com\/?p=57003","name":"Henlius Biotech Initiates Phase Ib\/II Study for HLX43 ADC Combinations in Colorectal Cancer - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-12T14:07:16+00:00","dateModified":"2026-02-12T14:07:19+00:00","description":"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced first patient dosing in a Phase Ib\/II clinical study evaluating HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), in combination with HLX07 (anti-EGFR mAb) or HanSiZhuang (serplulimab, PD-1 mAb) for advanced or metastatic colorectal cancer (CRC). The trial marks Henlius's entry into ADC-based immuno-oncology combinations, leveraging its self-developed antibody platforms and licensed toxin-linker technology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57003#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57003"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57003#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius Biotech Initiates Phase Ib\/II Study for HLX43 ADC Combinations in Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57003"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57003\/revisions"}],"predecessor-version":[{"id":57004,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57003\/revisions\/57004"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}